{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:12 23:20:22.323",
            "Expression": "mesenchymal allo-APZ2-EB",
            "NStudiesAvail": 430639,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "EBDASI: epidermolysis bullosa disease activity and scarring index; measured in percentage change to baseline score",
                              "iscorEB: instrument for scoring clinical outcome of research for epidermolysis bullosa; measured in percentage change to baseline score",
                              "iscorEB: instrument for scoring clinical outcome of research for epidermolysis bullosa; measured in percentage change to baseline score",
                              "EBDASI: epidermolysis bullosa disease activity and scarring index; measured in percentage change to baseline score",
                              "iscorEB: instrument for scoring clinical outcome of research for epidermolysis bullosa; measured in percentage change to baseline score",
                              "EBDASI: epidermolysis bullosa disease activity and scarring index; measured in percentage change to baseline score",
                              "iscorEB: instrument for scoring clinical outcome of research for epidermolysis bullosa; measured in percentage change to baseline score",
                              "A panel of inflammation markers will be measured and evaluated.",
                              "Pain assessment as per numerical rating scale (NRS) will be evaluated.",
                              "Itch assessment as per numerical rating scale (NRS) will be evaluated.",
                              "Assessment of quality of life data using an EB-specific quality of life questionnaire",
                              "A full physical examination will be performed and abnormal physical examination results will be evaluated and reported as AEs.",
                              "Body temperature will be evaluated at Screening, baseline, day 17, day 35 and week 12",
                              "Blood pressure will be evaluated at Screening, baseline, day 17, day 35 and week 12",
                              "Heart rate will be evaluated at Screening, baseline, day 17, day 35 and week 12"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score)",
                              "Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB), or last available post-baseline measurement if the Week 12 measurement is missing",
                              "Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB)",
                              "Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's EBDASI score)",
                              "Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's iscorEB)",
                              "Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's EBDASI score)",
                              "Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's iscorEB)",
                              "Inflammation (measured by panel of inflammation markers)",
                              "Pain assessment as per NRS",
                              "Itch assessment as per NRS",
                              "Differences in patient's quality of life in EB",
                              "Physical examination until Week 12;",
                              "Vital signs: Body temperature until Week 12;",
                              "Vital signs: Blood pressure until Week 12;",
                              "Vital signs: Heart rate until Week 12;",
                              "Overall survival at month 24"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "between baseline and week 12 post baseline (without LOCF)",
                              "Week 12 post baseline, or last available post-baseline measurement if the Week 12 measurement is missing (LOCF);",
                              "between baseline and week 12 post baseline (without LOCF)",
                              "between baseline and day 17 post baseline",
                              "between baseline and day 17 post baseline",
                              "between baseline and day 35 post baseline",
                              "between baseline and day 35 post baseline",
                              "between baseline and day 17, day 35 and week 12 post baseline",
                              "between baseline and day 17, day 35 and week 12 post baseline",
                              "between baseline and day 17, day 35 and week 12 post baseline",
                              "between baseline and day 17, day 35 and week 12 post baseline",
                              "At Screening, baseline, day 17, day 35 and week 12",
                              "At Screening, baseline, day 17, day 35 and week 12",
                              "At Screening, baseline, day 17, day 35 and week 12",
                              "At Screening, baseline, day 17, day 35 and week 12",
                              "month 24 post baseline"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03529877"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05464381"
                        ]
                  }
            ]
      }
}